

Fig. 1




Fig. 2




Fig. 3






Fig. 4

Conversion from Inj. SLR to Paltusotine:
Change in IGF-1 from Baseline to Steady State at Indicated Dose




Magnitude of Paltusotine Activity:
Change in IGF-1 from Steady State to 4 Weeks After Withdrawal



5 / 6

Fig. 5



*Target=Mean trough concentration observed to suppress IGF-1 comparable to that of LA-SRLs in acromegaly patients

Fig. 6

